DGX - EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy | Benzinga
Haystack Oncology, a Quest Diagnostics Inc. (NYSE:DGX) company, announced a research collaboration with Lisata Therapeutics Inc. (NASDAQ:LSTA).
Haystack Oncology developed Haystack MRD, a next-generation tumor-informed approach to measure minimal residual disease. Haystack MRD uses an error-corrected ctDNA technology to detect down to one ctDNA molecule in a million normal DNA molecules.
Lisata Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for advanced solid tumors.
Under the agreement, Lisata will deploy the Haystack MRD technology to detect circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus ...